JPRN-jRCTs051190095进行中（未招募）2 期
Phase II study of Pembrolizumab combined with carboplatin and pemetrexed for elderly patients with advanced non-squamous cell lung cancer
Kanai Kuninobu0 个研究点目标入组 22 人开始时间: 2020年1月17日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 22
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 75age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Has a histologically-confirmed or cytologically confirmed diagnosis of stage 3B, 3C or 4 of difficulgies with radical irradiation or postoperative recurrence non-squamous NSCLC
- •2. Documented absence or unknown of tumor activating EGFR mutations AND absence of ALK gene rearrangements
- •3. Documented absence or unknown of tumor activating ROS-1 mutations AND absence of tumor activating BRAF-V600E mutation
- •4. Has not received prior systemic treatment for their advanced/metastatic NSCLC. Subjects who received adjuvant or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed at least 6 months prior to the development of metastatic disease.
- •5. Be >=75 years of age
- •6. Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status.
- •7. Has adequate organ function
- •8. Has measurable disease based on RECIST 1.1 as determined by the local site investigator/radiology assessment. Target lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
- •9. Has a life expectancy of at least 3 months.
- •10. Subject has voluntarily agreed to participate by giving written informed consent for the trial.
排除标准
- •1. Has interstitial lung disease or a history of pneumonitis
- •2. Received radiation therapy to the lung that is >30 Gy within 6 months of the first dose of trial treatment.
- •3. Completedpalliative radiotherapy within 7 days of the first dose of trial treatment.
- •4. Has known symptomatic central nervous system (CNS) metastases
- •5. Has active double cancers (within 2 years)
- •6.Has known active Hepatitis B or C.
- •7. Has known history o f Human Immunodeficiency Virus (HIV)
- •8. Has symptomatic ascites or pleural effusion. A subject who is clinically stable following treatment for these conditions (including therapeutic thoraco- or paracentesis) is eligible.
- •9. Is unable to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs), other than an aspirin dose <= 1.3 g per day, for a 5-day period (8-day period for long-acting agents, such as piroxicam).
- •10. Has active autoimmune disease that has required systemic treatment (i.e. with use of disease modifying agents, corticosteroids up to 10 mg of prednisone, or immunosuppressive drugs).
- •11. Has known sensitivity to any component of cisplatin, carboplatin or pemetrexed
- •12. Is unable or unwilling to take folic acid or vitamin B12 supplementation.
- •13. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is otherwise not in the the best interest of the subject to participate, in the opinion of the treating Investigator.
研究者
相似试验
进行中（未招募）
1 期
A phase II study of Pembrolizumab plus Carboplatin in BRCA-related metastatic breast cancerEUCTR2016-001314-25-ITAZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA53
进行中（未招募）
2 期
A phase 2 study of pembrolizumab in combination with olaparib in patients with cervical cancer previously treated with platinum-based chemotherapyrecurrent or metastatic cervical cancercervical cancer ,Pembrolizumab,OlaparibJPRN-jRCT2031210096Hasegawa Kosei28
招募中
1 期
PERCEPTIOCTIS2023-508155-40-00ord-Ostdeutsche Gesellschaft Fuer Gynaekologische Onkologie e.V.33
进行中（未招募）
1 期
Study of pembrolizumab in combination with chemotherapy for patients suffering from recurrent ovarian cancerplatinum-sensitive recurrent low-grade serous ovarian cancer (including patients with primary peritoneal and / or fallopian tube adenocarcinoma)MedDRA version: 21.1Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-004083-25-DEOGGO e.V.33
招募中
1 期
A Phase 2 clinical trial of Pembrolizumab in combination with Carboplatin and Cabazitaxel in Aggressive Variant Metastatic Castration Resistant Prostate CancerCTIS2022-501139-17-01Fundación Oncosur42